Skip to content
Friday 28 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,792.54
-0.79%
DAX
26,367.24
+0.31%
CAC 40
8,319.87
0.00%
STOXX 50
6,424.73
-0.71%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 24 July 2013 6:58 am

More pharmaceutical firms could be implicated in Chinese bribery scandal

By: Chris Harlow

Add as a preferred source on Google

China’s official news agency Xinhua has indicated that more foreign and local pharmaceutical firms could be implicated in the corruption scandal gripping the industry.

This comes amid bribery accusations against GlaxoSmithKline, which is set to report its results at midday today.

It will not be surprising if more pharmaceutical companies and hospitals, domestic or international, are to be involved in probes in the days to come.

Xinhua said that 1,000 doctors, nurses and administrators at 73 hospitals in Zhangzhou city in the province of Fujian had been found taking bribes, and the Chinese government will be trying to clamp down on “malpractice” in the sector.

The following agencies are reportedly taking action: the ministry of public security, the ministry of health, the National Development and Reform Commission, and the State Administration for Industry and Commerce.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Morning Wire Content

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Andy Burnham hints at tax rises in Autumn Budget

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

  • Lloyds Bank and Halifax users unable to use app in latest outage

  • Economists urge Bank of England to halt bond sales as borrowing costs climb

More from Morning Wire

  • Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma

    Business Wire
  • Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

    Business Wire
  • Leeds NHS Innovation to Accelerate Global Adoption of AI-enabled Pathology for Cancer Diagnostics Through Epredia Partnership

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Bayer Leverkusen and RB Leipzig face ownership shake-up after 50+1 ruling

    Sport Business
    Two male soccer players, one in blue and one in white/red, vie for the ball on a green field.
  • Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook